Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

311.43 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Bio-Rad to Host Investor Day on February 25
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Bio-Rad to Participate in Fireside Chat During the 40th Annual J.P. Morgan Healthcare Conference on January 11
From Bio-Rad Laboratories, Inc.
Via Business Wire
Free COVID Tests: What Stocks Will Benefit?
The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits. 
Via Talk Markets
Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President
From Bio-Rad Laboratories, Inc.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Bio-Rad Laboratories, inc (BIO) Q3 2021 Earnings Call Transcript
BIO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Bio-Rad Reports Third-Quarter 2021 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Thermo Fisher Stock Strength Rating Climbs To 81; Medical Devices Maker Shows Market Leadership
Thermo Fisher Scientific shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Preview: Bio-Rad Laboratories's Earnings
Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021
From Bio-Rad Laboratories, Inc.
Via Business Wire
Fulgent Genetics Stock Meets 80-Plus Relative Strength Rating Benchmark
A Relative Strength Rating upgrade for Fulgent Genetics shows improving technical performance. 
Via Investor's Business Daily
15 Under 40, 14 Over 90: A Look At The Youngest And Oldest Members Of The Forbes 400 List
The annual Forbes 400 list highlights the people in the United States who have a ... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Medpace Stock Earns Relative Strength Rating Upgrade; Remains In Buy Zone
Ohio-based Medpace stock saw its Relative Strength Rating enter the 80-plus level while it stays in a buy zone. 
Via Investor's Business Daily
Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.